Loading company
Nkarta, Inc.
NKTX · Nasdaq · ·
Next earnings: November 9, 2026
$2.63-2.2%Sep 29 close
- 1M
- -2.6%
- 6M
- +20.1%
- 1Y
- +23.5%
- 5Y
- -91.2%
NKTX · Nasdaq · ·
Next earnings: November 9, 2026
$2.63-2.2%Sep 29 close
Nkarta, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$40.4M | -$23M | -75.69% |
| Profit per share | -$0.54 | -$0.31 | -74.19% |
| Free Cash Flow | -$24.4M | -$18.9M | -29.19% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Nkarta, Inc. has no earnings call transcript available.
“Expanding access to NKX019 in the communities where autoimmune patients already receive care is central to how we're advancing this program,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B 2 cells as well as those implicated in autoimmune disease. Nkarta is evaluating NKX019 in multiple autoimmune conditions.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nkarta, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.